BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 27253240)

  • 1. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?
    Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A
    Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia.
    Mauro FR; Caputo MD; Rosati S; Pepe S; De Benedittis D; De Luca ML; Foà R
    Expert Rev Hematol; 2018 Aug; 11(8):601-611. PubMed ID: 29969322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
    Daniel C; Mato AR
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.
    Rosenthal A
    Curr Hematol Malig Rep; 2017 Jun; 12(3):207-216. PubMed ID: 28439761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
    Jain N; O'Brien S
    Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia.
    Rossi D; Gerber B; Stüssi G
    Leuk Lymphoma; 2017 Jul; 58(7):1548-1560. PubMed ID: 27808579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Wendtner CM; Gregor M
    Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Agents for the Frontline Management of Chronic Lymphocytic Leukemia.
    Burger JA
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 8):7-12. PubMed ID: 27168204
    [No Abstract]   [Full Text] [Related]  

  • 10. The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.
    Jacobs RW; Awan FT; Leslie LA; Usmani SZ; Ghosh N
    Expert Rev Hematol; 2016 Dec; 9(12):1177-1187. PubMed ID: 27791448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of ibrutinib in chronic lymphocytic leukemia.
    Damon LE
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026
    [No Abstract]   [Full Text] [Related]  

  • 12. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
    Hill RJ; Lou Y; Tan SL
    Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
    Varma G; Johnson TP; Advani RH
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):543-54. PubMed ID: 27379948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCL-2 Inhibitors, Present and Future.
    Ryan CE; Davids MS
    Cancer J; 2019; 25(6):401-409. PubMed ID: 31764121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Perspectives on Therapy for Chronic Lymphocytic Leukemia.
    Awan FT; Al-Sawaf O; Fischer K; Woyach JA
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-10. PubMed ID: 32239979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?
    Milunović V; Mišura Jakobac K; Mandac Rogulj I; Martinović M; Radić-Krišto D; Ostojić Kolonić S
    Expert Rev Hematol; 2020 Jul; 13(7):771-779. PubMed ID: 32579408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia.
    Kittai AS; Woyach JA
    Cancer J; 2019; 25(6):428-435. PubMed ID: 31764124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.
    Arnason JE; Brown JR
    Curr Oncol Rep; 2017 Sep; 19(9):61. PubMed ID: 28755313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).
    Pettijohn EM; Ma S
    Curr Hematol Malig Rep; 2017 Feb; 12(1):20-28. PubMed ID: 28155013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.